方法对比
并排查看您选择的方法;存在差异的行会高亮显示。
| 等效性/非劣效性试验× | 交叉设计× | |
|---|---|---|
| 领域 | 实验设计 | 实验设计 |
| 方法族 | Hypothesis test | Hypothesis test |
| 起源年份≠ | 1987 | 1960 |
| 提出者≠ | Schuirmann, D.J. / EMA regulatory framework | Early formalized in clinical research literature; widely used since mid-20th century |
| 类型≠ | Parametric equivalence / non-inferiority test | Within-subject repeated-measures design |
| 开创性文献≠ | Schuirmann, D.J. (1987). A Comparison of the Two One-Sided Tests Procedure and the Power Approach. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680. link ↗ | Senn, S. (2002). Cross-over Trials in Clinical Research (2nd ed.). Wiley. ISBN: 978-0471496533 |
| 别名 | non-inferiority trial, bioequivalence study, active-control trial, Denklik ve Üstünlük Olmayan Çalışma (Equivalence / Non-Inferiority) | within-subject crossover, cross-over design, AB/BA design, Çapraz Desen (Crossover Design) |
| 相关 | 6 | 6 |
| 摘要≠ | An equivalence or non-inferiority trial is a clinical study design that tests whether a new intervention is clinically equivalent to, or no worse than, an established standard by a pre-specified margin. Codified in Schuirmann's 1987 Two One-Sided Tests (TOST) framework and embedded in EMA and FDA regulatory guidance, this design is the regulatory standard for generic drug approval and medical device testing. | A crossover design is an experimental design in which each participant receives all treatments under investigation, but in a different sequence and across separate time periods. Each subject thus acts as their own control, which substantially reduces between-subject variability and allows efficient treatment comparisons with smaller sample sizes. The approach has been central to clinical pharmacology and comparative research since the mid-20th century, with foundational methodology codified by Senn (2002) and Jones & Kenward (2014). |
| ScholarGate数据集 ↗ |
|
|